Literature DB >> 33758622

Insights into the role of ERp57 in cancer.

Danyang Song1, Hao Liu2, Jian Wu2, Xiaoliang Gao2, Jianyu Hao1, Daiming Fan1,2.   

Abstract

Endoplasmic reticulum resident protein 57 (ERp57) has a molecular weight of 57 kDa, belongs to the protein disulfide-isomerase (PDI) family, and is primarily located in the endoplasmic reticulum (ER). ERp57 functions in the quality control of nascent synthesized glycoproteins, participates in major histocompatibility complex (MHC) class I molecule assembly, regulates immune responses, maintains immunogenic cell death (ICD), regulates the unfolded protein response (UPR), functions as a 1,25-dihydroxy vitamin D3 (1,25(OH)2D3) receptor, regulates the NF-κB and STAT3 pathways, and participates in DNA repair processes and cytoskeletal remodeling. Recent studies have reported ERp57 overexpression in various human cancers, and altered expression and aberrant functionality of ERp57 are associated with cancer growth and progression and changes in the chemosensitivity of cancers. ERp57 may become a potential biomarker and therapeutic target to combat cancer development and chemoresistance. Here, we summarize the available knowledge of the role of ERp57 in cancer and the underlying mechanisms. © The author(s).

Entities:  

Keywords:  DNA repair.; ERp57/PDIA3; cancer; immune response; immunogenic cell death; unfolded protein response

Year:  2021        PMID: 33758622      PMCID: PMC7974888          DOI: 10.7150/jca.48707

Source DB:  PubMed          Journal:  J Cancer        ISSN: 1837-9664            Impact factor:   4.207


  4 in total

1.  Investigation of the effects of downregulation of jumping translocation breakpoint (JTB) protein expression in MCF7 cells for potential use as a biomarker in breast cancer.

Authors:  Madhuri Jayathirtha; Anca-Narcisa Neagu; Danielle Whitham; Shelby Alwine; Costel C Darie
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

2.  Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.

Authors:  Jing Zhang; Kai Wang; Tuersun Hainisayimu; Hui Li
Journal:  Oxid Med Cell Longev       Date:  2022-08-22       Impact factor: 7.310

Review 3.  ERp57/PDIA3: new insight.

Authors:  Silvia Chichiarelli; Fabio Altieri; Giuliano Paglia; Elisabetta Rubini; Marco Minacori; Margherita Eufemi
Journal:  Cell Mol Biol Lett       Date:  2022-02-02       Impact factor: 5.787

4.  Role and mechanism of chaperones calreticulin and ERP57 in restoring trafficking to mutant HERG‑A561V protein.

Authors:  Yujia Wu; Xiaoyan Huang; Zequn Zheng; Xi Yang; Yanna Ba; Jiangfang Lian
Journal:  Int J Mol Med       Date:  2021-07-02       Impact factor: 4.101

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.